@article {MATSUI3437, author = {TAKANORI MATSUI and NAOKI NAGATA and KEIJI HIRATA and SATOSHI OKAZAKI and SUMITO SATO and MASATO NAKAMURA and HOMIN KIM and KOJI OBA and JUNICHI SAKAMOTO and HIDEYUKI MISHIMA}, title = {Bi-weekly Capecitabine{\textendash}Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer {\textendash}The PHOENiX Trial}, volume = {36}, number = {7}, pages = {3437--3443}, year = {2016}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: This phase II study assessed the efficacy and toxicity of an intermittent weekly capecitabine regimen in combination with oxaliplatin (XELOX) plus bevacizumab as a first-line treatment of metastatic colorectal cancer (mCRC). Patients and Methods: Patients with measurable mCRC who were to receive first-line chemotherapy were enrolled onto this disease-oriented multicenter phase II trial. Patients with mCRC were required to have Eastern Cooperative Oncology Group performance status of 0 to 1, to be aged \>20 years, and to have adequate organ function. Localization of tumor, toxicities, response rate, progression-free survival (PFS) and time to progression (TTP) were studied. Capecitabine dose was 2,500 mg/m2/day on days 1-7 (n=47) and was increased to 3,000 mg/m2/day (n=5) in combination with oxaliplatin (85 mg/m2) and bevacizumab (5 mg/kg), repeated every 2 weeks. Results: A total of 51 patients were enrolled from 14 institutions from December 2011 to July 2012. The median age was 66 (range=38-85) years, 29 (56.9\%) had colonic cancer and 22 (43.1\%) had rectal cancer in this study. Pertinent grade 3/4 toxicities were neutropenia (13.7\%), peripheral neuropathy (13.7\%), hypertension (13.7\%), gastrointestinal perforation (3.9\%), and hand-foot syndrome (5.9\%). The response rate was 51\% (one complete and 25 partial responses). Median PFS and TTP were 344 days and 196 days, respectively. Median overall survival has not been reached yet. Conclusion: The first-line treatment of mCRC using a biweekly combination of XELOX plus bevacizumab can also be administered safely and effectively in Japan. It is suggested that this regimen is an appropriate option for the treatment of mCRC.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/36/7/3437}, eprint = {https://ar.iiarjournals.org/content/36/7/3437.full.pdf}, journal = {Anticancer Research} }